Search | Clinical Trials Finder

Conditions: Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
Interventions: Clinical Decision Support; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 1,543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia
Interventions: Momelotinib; Drug
Lead sponsor: Sierra Oncology LLC - a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 12 more

Conditions: Blood Coagulation
Interventions: mgt of bleeding concerns/complications of oral anticoagulants; Other
Lead sponsor: Hospital Quality Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 9
States / cities: Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more

Conditions: Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Interventions: Velinotamig specified dose on specified days.; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Webster, Texas

Conditions: Hemophilia A
Interventions: FVIII products, Conventional FVIII replacement therapies; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions: Immune Globulin Intravenous (Human), 10%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more

Conditions: Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
Interventions: Damoctocog alfa pegol (Jivi, BAY94-9027); Biological
Lead sponsor: Bayer; Industry
Eligibility: 7 Years to 11 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
Interventions: Arsenic Trioxide, Ascorbic Acid, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Dietary Supplement · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 19 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hemophilia A
Interventions: Bypassing Agents, FVIII Replacement; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Santa Monica, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Polycythemia Vera, Essential Thrombocythemia
Interventions: RG7388, Pegasys; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Little Rock, Arkansas • Long Beach, California • Tampa, Florida + 15 more

Conditions: Severe Hemophilia A
Interventions: rF.VIII; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more

Conditions: Blood Coagulation Disorders
Interventions: FFP Infusion; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 4 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 15
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 11 more

Conditions: Hemophilia A
Interventions: Ideal Body Weight First, Actual Body Weight First; Other
Lead sponsor: Bloodworks; Other
Eligibility: 12 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Portland, Oregon • Seattle, Washington • Spokane, Washington

Conditions: Hemophilia A, Hemophilia B
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma
Interventions: Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP); Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Prefibrotic/Early Primary Myelofibrosis
Interventions: Azacitidine, Pevonedistat, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemophilia A
Interventions: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 75 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Peoria, Illinois • Winston-Salem, North Carolina • Cleveland, Ohio

Conditions: Chronic Myeloproliferative Disorders
Interventions: imatinib mesylate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: Uniplas, Cryosupernatant plasma; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Centreville, Virginia

Conditions: Acquired Thrombotic Thrombocytopenic Purpura
Interventions: Caplacizumab, Standard of Care; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: St Louis, Missouri • Valhalla, New York • Durham, North Carolina + 5 more

Conditions: Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions: SR604, Placebo; Drug
Lead sponsor: Equilibra Bioscience LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 7 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 9
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more

Search by objective public record fields.

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Safety of Oral Anticoagulants Registry

A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

Reproductive Health in Men and Women With Vasculitis

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures

Comparison of Ideal vs. Actual Weight Base Factor Dosing

Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

BAX 802 in CHA With Inhibitors

Imatinib Mesylate in Treating Patients With Myelofibrosis

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A